Pharmaceutical industry news

Non-pharmacological behavior management techniques in pediatric dentistry: A narrative <span style="font-size: 1rem;">review and clinical insights</span>

Genital fungal infections in type 2 diabetes: Clinical, behavioral, and microbiota correlates of SGLT2 inhibitor therapy

Characterization of serotypes, diversity and drug susceptibiliy among clinical Salmonella isolates

Romanian National Study on the Epidemiology of Inflammatory Bowel Diseases

Clinical Research Trends of Laser Therapy for Onychomycosis in Korea, China, and Japan, and Its Applicability in Korean Medicine: A Scoping Review

Clinical Research Trends in Lidocaine Injection at Acupoints: A Scoping Review

Design, Synthesis, and Biological Evaluation of Potent Cognition-Improved Compounds Targeting AMPA Receptor Based on CX717

An Improved Brain-Penetrating Nanoformulation of the VIPR2 Antagonist Peptide KS-133 for Treating Cognitive Impairment in Schizophrenia

Approach to Personalizing the Treatment of Osteoporosis

Nonpharmacological multicomponent intervention for mild cognitive impairment with a family-patient approach: protocol for the pilot clinical trial—INTERCOG study

Clinical outcomes of capsular repair versus non-repair after hip arthroscopy for femoroacetabular impingement: a meta-analysis

Investigating the effect of intermittent fasting (time-restricted eating) with and without calorie restriction compared to calorie restriction on anthropometric parameters, depression score, and metabolic factors in patients with major depression disorder and obesity: a study protocol for a randomiz

Multidisciplinary telemedicine intervention for ICU recovery: the TelePORT feasibility randomized trial

Epigenetic safety of in vitro maturation in PCOS: genome-wide DNA methylation profiling of cord blood from a randomized controlled trial

HES1 inhibition overcomes CDK4/6 inhibitor resistance by targeting cancer stemness in lung adenocarcinoma

From paradox to target: IFN-β hijacks MEK signaling to drive a cell death-evading dormant phenotype in colorectal cancer

Nasal eosinophilia in pediatric non-allergic rhinitis: correlation with clinical severity scales

Integrated analysis of gut microbiota, serum metabolomics, and proteomics reveals novel associations with clinical symptoms in patients with cerebral infarction

Clinical Resource/Quick Reference

Temporal Changes in Left Ventricular Strain in Typical and Atypical Left Bundle Branch Block Patients: A Follow‐up Study

Synergistic Cardioprotection of Colchicine and Hyperbaric Oxygen Therapy in a Rat Model of Remote Ischemia‐Reperfusion Injury

A Novel Device to Improve the Tolerability of Intranasal Corticosteroid Sprays for Allergic Rhinitis and Postoperative Chronic Rhinosinusitis: A Crossover Trial

Modulation of Respiratory Diseases by the Endocannabinoid System: A Therapeutic Perspective

Feasibility and Process Evaluation of CArdiac Brief INtervention (CABIN) in Patients with ST-Elevation Myocardial Infarction: A Mixed-Method, Pilot Randomised Controlled Trial.

Right Ventricular to Pulmonary Artery Coupling and Clinical Outcomes after Interatrial Shunting in Heart Failure: Exploratory Analysis of the PRELIEVE study

Rivaroxaban for the prevention of atherothrombotic events in advanced CKD: are we off TRACK?

Case Series on the Efficacy of Daratumumab in Treating Patients with Anti-Interferon-Gamma Autoantibodies

A second case of recessive mosaicism in <i>ABCA12</i> causing a congenital unilateral epidermal nevus

Hydrogel-based drug delivery systems for oral mucositis: a systematic review of preclinical models and translational perspectives

Using NAL-NL3 in clinical practice: a modular NAL fitting system for real-world listening needs

Patient-derived organoids as a predictive platform for drug sensitivity in bladder cancer

Screen for Tissue-Specific Markers of Drug-Induced Phospholipidosis Using Mass Spectrometry Imaging

The CARE Program: An Initiative of Patient-Focused Drug Development for Rare Diseases by NMPA

Prevalence, predictors, and clinical impact of vitamin D deficiency on 12-month outcomes in hip fracture patients

Multiple drugs

Methadone

Fluoxetine/Lamotrigine

Redispersible nanoalum-adjuvanted hepatitis B vaccine microneedles with enhanced immunogenicity

Transparent keratin nanocomposite films incorporating silver nanoparticles and aloe vera for wound management

Traditional Buddhist Mindfulness Versus Secular Mindfulness-Based Cognitive Therapy for Residual Depressive Symptoms in Patients Treated for Depressive Disorder: A Pilot Randomized Controlled Trial

Optimizing tourniquet pressures in knee arthroscopy: an international survey on current practice and a double-blind randomized trial

Pharmacogenomic characterization of a uric acid metabolism-related signature associated with prognosis and drug sensitivity in gastric cancer

Bovine Milk–Derived Extracellular Vesicles as Emerging Drug Delivery Platforms: Current Advances, Applications and Challenges

Clinical Pharmacists in Primary Care: A Real‐World Experience From São Paulo, Brazil

The Permissible Use of the Pernkopf Atlas: A Single‐Case Qualitative Study of the Vienna Protocol

Price to earnings forward of Suzhou Fengbei Biotech Stock Co., Ltd. Class A – SSE:603334

EchoNous Expands Kosmos Clinical Capabilities with Vascular Auto Flow; Advanced Cardiac and Connectivity Tools

EMA: Amgen, Vifor Inflammatory Drug’s Benefits No Longer Outweigh Risks

FDA Approves Viridian's Lumvoa for Thyroid Eye Disease (TED)

This Biotech ETF Has Almost Doubled in 13 Months. Money Is Flowing In. -- Barrons.com

Pioneering projects to transform obesity care, backed by £85 million from government and industry

A dozen cutting-edge projects will benefit thousands of patients battling obesity across the UK.

FDA approves Viridian eye drug, stoking competition with Amgen’s Tepezza

Medpace (MEDP) Has a Backlog-and-Execution Engine Bigger Than a Biotech-Funding Scare

Argentina joins Chinese coronavirus vaccine trial

Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results

Viridian Therapeutics announced that its innovative drug Lumvoa™ (generic name: veligrotug-vvze) has been approved by the U.S. Food and Drug Administration (FDA) and officially launched for the treatment of Thyroid Eye Disease (TED).

Price to earnings forward of Sunhawk Vision Biotech, Inc. – TPEX:7759

Is Axsome Therapeutics (AXSM) Using Solriamfetol’s Phase 3 ADHD Trial To Redefine Its CNS Strategy?

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

More Than 900,000 Bottles of Heart and Kidney Drugs Recalled: FDA Notice